Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxxinity, Inc. - Class A Common Stock (NQ: VAXX )

0.4461 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxxinity, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company’s clinical data in Parkinson’s disease 
From Vaxxinity, Inc.
Via GlobeNewswire
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
VAXX stock results show that Vaxxinity beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
From Vaxxinity, Inc.
Via GlobeNewswire
Recap: Vaxxinity Q3 Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients 
From Vaxxinity, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
From Vaxxinity, Inc.
Via GlobeNewswire
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Vaxxinity to Present at Upcoming Investor Conferences in September
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial
Vaxxinity Inc (NASDAQ: VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational  
Via Benzinga
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
From Vaxxinity, Inc.
Via GlobeNewswire
Recap: Vaxxinity Q1 Earnings
Vaxxinity (NASDAQ:VAXX) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Vaxxinity beat estimated earnings by... 
Via Benzinga
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Vaxxinity, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
From Vaxxinity, Inc.
Via GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
From Vaxxinity, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.